Charles River Laboratories International Inc(CRL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:13 PM ET (Korea 9/12 05:13)
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -4.85 | Insider Own | 1.12% | Shs Outstand | 47.7M | Perf Week | -5.14% |
| Market Cap | 13.28B | Forward P/E | 21.85 | EPS next Y | 12.49% | Insider Trans | -23.69% | Shs Float | 47.2M | Perf Month | -2.15% |
| Enterprise Value | 16.15B | PEG | 1.93 | EPS next Q | 2.96 | Inst Own | 121.2% | Short Float | 5.37% | Perf Quarter | 47.96% |
| Income | -0.24B | P/S | 3.32 | EPS this Y | 10.11% | Inst Trans | -1.53% | Short Ratio | 2.85 | Perf Half Y | 82.27% |
| Sales | 4.00B | P/B | 4.68 | EPS next 5Y | 11.31% | ROA | -3.16% | Short Interest | 2.54M | Perf YTD | 39.49% |
| Book/sh | 59.5 | P/C | 61.37 | EPS past 3/5Y | - | ROE | -7.7% | 52W High | -8.26% ($303.30) | Perf Year | 74.2% |
| Cash/sh | 4.53 | P/FCF | 35.84 | Sales past 3/5Y | 0.33% 6.55% | ROIC | -4.06% | 52W Low | 92.89% ($144.26) | Perf 3Y | 39.37% |
| Dividend Est. | - | EV/EBITDA | 19.27 | EPS Y/Y TTM | -268.79% | Gross Margin | 32.63% | Volatility(W/M) | 2.27% 3.01% | Perf 5Y | -36.9% |
| Dividend TTM | - | EV/Sales | 4.04 | Sales Y/Y TTM | -0.74% | Oper. Margin | 13.51% | ATR (14) | 8.91 | Perf 10Y | 253.3% |
| Dividend Ex-Date | - | Quick Ratio | 1.04 | EPS Q/Q | -102.91% | Profit Margin | -5.96% | RSI (14) | 51.2 | Recom | 1.89 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | -2.72% | SMA20 | -3.32% ($287.82) | Beta | 1.41 | Target Price | $293 |
| Payout | - | Debt/Eq | 1.07 | Earnings | 2026/8/5 | SMA50 | 7.48% ($258.89) | Rel Volume | 0.86 | Prev Close | $273 |
| Employees | 19700 | LT Debt/Eq | 1.07 | EPS/Sales Surpr. | 10.13% 2.75% | SMA200 | 37.46% ($202.43) | Avg Volume(3M) | 0.89M | Price | $278.26 |
| IPO | 2000/6/23 | Option/Short | Yes/Yes | Trades | 9922 | Volume | 767,678 | Change | 1.93% |
Company
CRL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global contract research organization (CRO) that supports the preclinical stage of new drug development. The company supports the entire early-stage research and development process for pharmaceutical and biotech companies, including research models, drug discovery, safety evaluation, and contract manufacturing, and is a healthcare services company with a leading global position in the preclinical CRO field.
Over the past 1 year, on the higher side
8% below its 1-year high.
CRL has weak earning power
13.51% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +39.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 121.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SAEF 0.02%
RSPH 0.02%
EPAI 0.02%
BBH 0.01%
FTXH 0.01%It ranks #4 in the industry
Based on market cap of $13B.
CRL $13B PER -
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is CRL?
CRL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CRL?
The market cap of CRL is approximately $13.3B, ranking 788 within its sector.
What is the 52-week high and low for CRL?
CRL has recorded a 52-week high of $303.30 and a low of $144.26.
